Istituto di Ematologia di Bologna

Recent papers from Istituto di Ematologia di Bologna

1. Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCLAmerican Journal of Hematology · 2026
2. Bispecific antibodies targeting B‐cell maturation antigen in multiple myeloma: Current clinical applications, challenges and future directionsCancer · 2026
3. Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma: Final Analysis of the Phase 2 ROSEWOOD StudyTargeted Oncology · 2026
4. Discordant marrow MRD and PET ‐ CT in myeloma: A four‐state language for joint reportingBritish Journal of Haematology · 2026
5. Patients’ preferences for accepting risks and uncertainty in AML treatments within European public health care systems: a cross-sectional study in Finland, Italy, and GermanyLeukemia & lymphoma/Leukemia and lymphoma · 2026
6. Navitoclax monotherapy or in combination with ruxolitinib in patients with JAK2 inhibitor-treated myelofibrosis: results from the phase 2 REFINE and phase 3 TRANSFORM-2 studiesLeukemia & lymphoma/Leukemia and lymphoma · 2026
7. Real-world Italian experience with asciminib in chronic myeloid leukaemia–chronic phase: case series and drug profile overviewAnnals of Hematology · 2026
8. Primary mediastinal B-cell lymphoma: a nationwide real-life retrospective study of first-line treatment approaches in ItalyHaematologica · 2026
9. Different treatment eras for relapsed and refractory primary mediastinal B-cell lymphoma patients: accessibility to CAR T cells is associated with a better prognosis in a pooled analysis of the REPRIME-FIL and the CART-SIE studiesHaematologica · 2026
10. Circulating tumor plasma cells quantification in newly diagnosed transplant ineligible real world multiple myeloma patients: Comparison of single‐platform flow cytometry versus next generation flowCytometry Part B Clinical Cytometry · 2026
11. Transcriptomic profile and endothelial changes during differentiation syndrome in acute promyelocytic leukemiaAnnals of Hematology · 2026
12. Dynamic on-treatment prognosis refinement in molecularly defined lower-risk myelofibrosisAnnals of Hematology · 2026
13. Omaveloxolone potentiates BET protein inhibition under hypoxia by disrupting metabolic and translational programs in acute myeloid leukemia cellsJournal of Translational Medicine · 2026
14. The evolution of Extravascular Cardioverter Defibrillator implantation: feasibility in a purely electrophysiologic settingEP Europace · 2026
15. Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real‐life study from European Myeloma Network ( EMN ) ItalyBritish Journal of Haematology · 2026
16. Efficacy and Potential Limitation of the Menin Inhibitor Revumenib Outside Clinical Trials: Extramedullary Response with Central Nervous System Escape in a Case of KMT2A-Rearranged Acute Myeloid LeukemiaTargets · 2026
17. Advancing chemogenomic strategies for functional precision medicine in relapsed-refractory T-ALL and ETP-ALL: the GIMEMA ALL2720 trialnpj Precision Oncology · 2026
18. Optimizing the Real-World Use of BCMA-Targeted T-Cell-Engaging Therapies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: An Italian Modified Delphi ConsensusCancers · 2026
19. Circulating plasma cells (polyclonal and monoclonal) as markers of an aggressive multiple myeloma phenotypeScientific Reports · 2026
20. Automated Deauville Score computation from baseline [¹⁸F]FDG PET/CT predicts progression-free survival in multiple myeloma: a radiogenomic frameworkEuropean Journal of Nuclear Medicine and Molecular Imaging · 2026